Etracker Debug:
	et_pagename = "Journal of Pediatric Endocrinology and Metabolism|jpem|C|[EN]"
	
        
Jump to ContentJump to Main Navigation

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Editorial Board Member: Darendeliler, Feyza / Gustafsson, Jan / Luo, Feihong / Mericq, Veronica / Lanes M. D., Roberto / Battelino, Tadej / Buyukgebiz, Atilla / Cassorla, Fernando / Chrousos, George P. / Cutfield, Wayne / Fideleff, Hugo L. / Hershkovitz, Eli / LaFranchi, Stephen H. / Mohn, Angelika / Root, Allen W. / Rosenfeld, Ron G. / Wabitsch, Martin / Werther, George / Zadik, Zvi

12 Issues per year

IMPACT FACTOR 2013: 0.711

VolumeIssuePage

Issues

Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes

Murat Baykara1 / Mehmet Emre Atabek2 / 2 / Selim Kurtoglu3

1Department of Radiology, School of Medicine, Erciyes University, Kayseri, Turkey

2Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, School of Medicine, Necmettin Erbakan University, Konya, Turkey

3Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, School of Medicine, Erciyes University, Kayseri, Turkey

Corresponding author: Beray Selver Eklioglu, Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Necmettin Erbakan University, Konya 42080, Turkey, Phone: +90 332 223 6350, Fax: +90 332 223 6181

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 26, Issue 1-2, Pages 19–24, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem-2012-0166, November 2012

Publication History

Received:
2012-05-22
Accepted:
2012-09-17
Published Online:
2012-11-09

Abstract

Objective: The purpose of this study was to determine whether oral pentoxifylline (PTX) would improve retinal microvascular hemodynamics in children with type 1 diabetes mellitus (DM).

Patients and methods: Non-invasive ultrasonographic measurements were made in 56 type 1 diabetic patients. The diabetic patients were matched first in terms of age, diabetes duration, then one individual within each pair was randomized into a pentoxifylline group and a control group. Pentoxifylline was administered for 6 months. We investigated the change of peak systolic velocity (PSV), end diastolic velocity (EDV), pulsatility index (PI), and resistivity index (RI) of central retinal artery (CRA) at 6 months after pentoxifylline. We investigated the relationship between PI, RI and carotide cross-sectional compliance (C-CSC).

Results: In comparison to changes in CRA measurements between the two groups, the pentoxifylline treatment group had significantly lower PI values (p=0.01). The RI, PSV and EDV were lower in pentoxifylline group but not statistifically different. There was a positive correlation between CRA PSV and carotid Vmax (cm/s) (r=0.29, p=0.02) and also C-CSC (r=0.27, p=0.03). In addition, there was a positive correlation between PI and C-CSC (r=0.3, p=0.02). In the pentoxifylline group there was a significant reduction in systolic blood pressure, diastolic blood pressure, microalbuminuria and an increase in HDL level.

Conclusion: Our results suggest that pentoxifylline may have a protective action for diabetic retinopathy and might modulate risk factors for atherosclerosis in type 1 diabetes.

Keywords: central retinal artery; common carotid artery; pentoxifylline; type 1 diabetes

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.